Lobe Sciences Ltd. Announces Private Placement to Fund Clinical Developments

Lobe Sciences Ltd., a biopharmaceutical company, recently announced a non-brokered private placement. This offering involves 24,705,880 common shares priced at $0.085 each, totaling approximately $2.1 million in gross proceeds.

The company aims to use these funds for various purposes, including enhancing cash reserves and continuing the clinical development of the S-100 molecule by its subsidiary, Applied Lipid Technology. This initiative also supports general corporate needs and working capital.

The execution of the private placement is contingent upon receiving regulatory approvals, including from the Canadian Securities Exchange. The issued securities will be subjected to a four-month hold period under Canadian laws. These securities are not registered under the U.S. Securities Act of 1933 and cannot be sold in the United States without registration or an applicable exemption.